Faeth Therapeutics, a clinical-stage biotechnology company advancing therapies that systematically target tumor metabolism, ...
MedPage Today on MSN
Endocrine Therapy Resistance in HR+/HER2- Breast Cancer: A Common Clinical Challenge
Endocrine therapy typically slows cell cycle progression by reducing cyclin D1, which partners with CDK4/6 to promote cell ...
Low-dose aspirin reduced colorectal cancer (CRC) recurrence rates by more than half in patients with tumors harboring mutations in the PI3K signaling pathway, according to findings from the phase 3 ...
Scientists have found a new way to stop cancer growth without damaging healthy cells. Researchers from the Francis Crick ...
MedPage Today on MSN
For Your Patients: Next Steps If There Is Resistance to Endocrine Therapy
When cancer progresses on endocrine therapy, the next step is likely either a biopsy to gather tissue for testing or a liquid ...
Celcuity Inc. surges to a $2B valuation on strong phase 3 data for gedatolisib in hormone-positive breast cancer. Read why ...
A comprehensive, multi-phase investigation published in Advanced Science suggests that the amino acid tryptophan (Trp) may be a key determinant of therapeutic response to conventional synthetic ...
An international research team has identified a previously unknown mechanism by which the breast cancer drug tamoxifen can increase the risk of secondary tumors in the uterus. The study shows that ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results